Targeting the NF-κB Pathway in Cancer Therapy
Targeting the NF-κB Pathway in Cancer Therapy
复制标题
DOI：
10.1016/j.soc.2013.06.011
复制
发表时间：
2013-10-01
影响因子：
1.9
通讯作者：
Cusack, James C., Jr.
中科院分区：
文献类型：
--
作者：
Erstad, Derek J.;Cusack, James C., Jr.
大多数NF-κ B抑制剂靶向IKK复合物、IKB蛋白或NF-κ B转录因子。最有前途的抑制剂类别包括抗氧化剂、抗氧化剂化合物、天然化合物、他汀类药物、蛋白酶体抑制剂、IKK β抑制剂、生物制剂、基因治疗和RNA干扰。靶向NF-κ B受到内在途径复杂性、与其他途径的串扰、缺乏生物标志物、药物特异性差、耐药性和药物递送困难的限制。未来的NF-κ B B靶向将通过更好地理解该途径、更特异的抑制剂和多模式治疗来改善。
Most NF-kappa B inhibitors target the IKK complex, IKB proteins, or NF-kappa B transcription factors. The most promising classes of inhibitors include antioxidants, antiinflammatory compounds, natural compounds, statins, proteasome inhibitors, IKK beta inhibitors, biologics, gene therapy, and RNA interference. Targeting NF-kappa B is limited by intrinsic pathway complexity, cross-talk with other pathways, a lack of biomarkers, poor drug specificity, drug resistance, and difficulty with drug delivery. Future NF-kappa B targeting will be improved through better understanding of the pathway, more specific inhibitors, and multimodality therapies.